provera
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.92 | $55.07 (0%) | 🛒 Add to cart |
| 90 | $0.85 | $82.60 $76.10 (8%) | 🛒 Add to cart |
| 120 | $0.81 | $110.14 $97.12 (12%) | 🛒 Add to cart |
| 180 | $0.77 | $165.21 $139.18 (16%) | 🛒 Add to cart |
| 270 | $0.75 | $247.81 $202.26 (18%) | 🛒 Add to cart |
| 360 | $0.74
Best per pill | $330.42 $265.34 (20%) | 🛒 Add to cart |
Synonyms
| |||
Provera, known generically as medroxyprogesterone acetate, is a synthetic progestin medication primarily used in gynecology and oncology. It’s not a dietary supplement or medical device but a prescription pharmaceutical with specific hormonal activity. This monograph will cover its composition, mechanisms, clinical applications, and practical considerations based on current evidence and clinical experience.
Provera: Hormone Regulation for Gynecological and Oncological Conditions - Evidence-Based Review
1. Introduction: What is Provera? Its Role in Modern Medicine
Provera contains medroxyprogesterone acetate as its active pharmaceutical ingredient, functioning as a synthetic progestogen that mimics the effects of natural progesterone. This medication has been part of clinical practice for decades, primarily addressing hormone-sensitive conditions where progesterone activity is therapeutic. Unlike natural progesterone, medroxyprogesterone acetate offers greater oral bioavailability and prolonged duration of action, making it particularly valuable in managing menstrual disorders, providing contraceptive coverage, and treating certain hormone-responsive cancers.
The significance of Provera lies in its ability to modulate endometrial tissue response to estrogen, thereby preventing endometrial hyperplasia in women receiving estrogen therapy and treating various gynecological conditions characterized by progesterone deficiency or imbalance. Its role extends beyond reproductive health to include palliative management of advanced endometrial, renal, and breast cancers in specific clinical scenarios.
2. Key Components and Bioavailability Provera
The pharmaceutical composition of Provera is centered on medroxyprogesterone acetate, a synthetic derivative of 17α-hydroxyprogesterone. The molecular structure includes additional acetate groups at the 17α position, which significantly enhances its metabolic stability compared to natural progesterone. This structural modification reduces first-pass metabolism and extends half-life, allowing for less frequent dosing regimens in clinical practice.
Available formulations include:
- Oral tablets (2.5mg, 5mg, 10mg)
- Injectable suspension (150mg/mL for depot administration)
- Combination products with estrogens
The bioavailability of oral medroxyprogesterone acetate ranges from 5-10%, with peak plasma concentrations occurring within 2-4 hours post-administration. Food intake does not significantly affect absorption, though consistency in administration timing relative to meals may help maintain stable plasma levels. The injectable form provides sustained release over 3 months, making it particularly useful for long-term management and contraception.
3. Mechanism of Action Provera: Scientific Substantiation
Provera exerts its effects through binding to intracellular progesterone receptors, forming hormone-receptor complexes that translocate to the nucleus and modulate gene transcription. The medication demonstrates both agonist and partial antagonist activity depending on tissue type and hormonal milieu.
The primary mechanisms include:
- Endometrial transformation: Induces secretory changes in estrogen-primed endometrium
- Pituitary suppression: Inhibits gonadotropin secretion, preventing ovulation
- Cervical mucus alteration: Increases viscosity, creating barrier to sperm penetration
- Antiestrogenic effects: Competes with estrogen receptors in certain tissues
In oncological applications, Provera promotes differentiation of endometrial cells and inhibits estrogen-stimulated growth in hormone-sensitive malignancies. The antiproliferative effects result from complex interactions with growth factors and cell cycle regulators, though resistance mechanisms can develop with prolonged use.
4. Indications for Use: What is Provera Effective For?
Provera for Secondary Amenorrhea
Restores menstrual bleeding in women with progesterone deficiency following adequate estrogen priming. Treatment typically involves 5-10mg daily for 5-10 days, with withdrawal bleeding expected within 3-7 days after discontinuation.
Provera for Abnormal Uterine Bleeding
Manages dysfunctional uterine bleeding by stabilizing endometrial tissue and promoting organized shedding. Dosing regimens vary based on bleeding severity and patient characteristics.
Provera for Endometrial Hyperplasia
Prevents progression to endometrial carcinoma in women with simple hyperplasia without atypia, typically administered cyclically (10-20mg daily for 12-14 days per month).
Provera for Contraception
The depot formulation provides highly effective contraception lasting 3 months per injection, primarily through suppression of ovulation and cervical mucus changes.
Provera for Endometrial Cancer
Used in advanced or recurrent disease, particularly in younger women wishing to preserve fertility or patients with contraindications to more aggressive treatments.
Provera for Breast Cancer
Occasionally employed in metastatic hormone receptor-positive disease, though largely superseded by aromatase inhibitors in postmenopausal women.
5. Instructions for Use: Dosage and Course of Administration
| Indication | Dosage | Frequency | Duration | Administration Notes |
|---|---|---|---|---|
| Secondary Amenorrhea | 5-10mg | Once daily | 5-10 days | Begin after estrogen priming |
| Abnormal Uterine Bleeding | 5-10mg | Once daily | 5-10 days | May require higher doses for heavy bleeding |
| Endometrial Hyperplasia | 10-20mg | Once daily | 12-14 days/month | Continue for 3-6 months with endometrial sampling |
| Contraception | 150mg | Every 3 months | Intramuscular | Deep gluteal or deltoid injection |
| Endometrial Cancer | 200-600mg | Daily | Continuous | Higher doses for advanced disease |
The injectable form should be administered using strict aseptic technique, with vigorous shaking of the vial immediately before drawing up the medication. Rotation of injection sites is recommended to prevent localized reactions.
6. Contraindications and Drug Interactions Provera
Absolute Contraindications:
- Active thrombophlebitis or thromboembolic disorders
- History of hormone-sensitive cancers (except when used for treatment)
- Undiagnosed abnormal genital bleeding
- Known hypersensitivity to medroxyprogesterone acetate
- Active liver disease or hepatic tumors
- Suspected pregnancy
Relative Contraindications:
- History of depression
- Migraine with aura
- Cardiovascular disease risk factors
- Diabetes mellitus with vascular complications
- Renal impairment
Significant Drug Interactions:
- Enzyme inducers: Carbamazepine, phenytoin, rifampin may reduce efficacy
- Anticoagulants: May alter response to warfarin
- Corticosteroids: Potential additive effects on glucose metabolism
- Thyroid hormones: May alter thyroid hormone binding
Safety during pregnancy remains controversial, with some studies suggesting possible association with genital abnormalities in male fetuses when used during first trimester. Breastfeeding considerations include potential passage into milk and effects on milk production.
7. Clinical Studies and Evidence Base Provera
The evidence supporting Provera use spans several decades, with evolving understanding of benefits and risks. Key studies include:
Women’s Health Initiative (WHI) - While primarily evaluating estrogen-progestin combinations, provided insights into cardiovascular risks associated with synthetic progestins in postmenopausal women.
PEARL Trial - Demonstrated efficacy of depot medroxyprogesterone acetate for contraception, with 99% effectiveness rates when administered properly.
Endometrial Cancer Studies - Multiple trials have shown response rates of 15-25% in advanced endometrial cancer, particularly in well-differentiated tumors expressing progesterone receptors.
Bone Mineral Density Research - Long-term depot use associated with reversible bone density reduction, leading to current recommendations regarding duration of use and monitoring.
Recent meta-analyses continue to support the role of Provera in managing secondary amenorrhea and abnormal uterine bleeding, though emphasize individualizing therapy based on patient characteristics and risk factors.
8. Comparing Provera with Similar Products and Choosing a Quality Product
When comparing Provera to other progestins, several factors merit consideration:
Versus Micronized Progesterone:
- Provera has greater metabolic stability but different side effect profile
- Micronized progesterone may have better cardiovascular safety profile
- Provera offers more predictable endometrial effects
Versus Other Synthetic Progestins:
- Norethindrone has more androgenic activity
- Drospirenone offers anti-mineralocorticoid effects
- Levonorgestrel has greater potency per milligram
Quality Considerations:
- Verify manufacturer reputation and regulatory approval
- Check for consistent tablet appearance and proper packaging
- Ensure appropriate storage conditions have been maintained
- Consider cost relative to therapeutic objectives
Generic alternatives containing medroxyprogesterone acetate provide comparable efficacy at reduced cost, though some patients report differences in excipient-related side effects.
9. Frequently Asked Questions (FAQ) about Provera
What is the recommended course of Provera to achieve results for abnormal bleeding?
Typically 5-10 days of therapy, with bleeding cessation expected within 3-5 days of initiation and withdrawal bleeding occurring after discontinuation.
Can Provera be combined with estrogen therapy?
Yes, this represents one of the primary indications - protecting the endometrium during estrogen replacement in postmenopausal women.
How long does Provera take to regulate menstrual cycles?
Most women experience cycle regulation within 1-3 months of cyclic therapy, though individual response varies.
What monitoring is required during long-term Provera use?
Regular blood pressure checks, periodic lipid and glucose assessment, and bone density monitoring with extended depot use.
Can Provera cause weight gain?
Some women report fluid retention and modest weight changes, though studies show inconsistent results regarding causal relationship.
Is Provera safe for women with history of blood clots?
Generally contraindicated in women with personal history of thromboembolism due to increased recurrence risk.
10. Conclusion: Validity of Provera Use in Clinical Practice
Provera remains a valuable therapeutic option in specific clinical scenarios, particularly for menstrual regulation, endometrial protection, and certain oncological applications. The risk-benefit profile favors use when indications are appropriate and contraindications have been carefully considered. Ongoing research continues to refine our understanding of optimal dosing strategies and long-term safety considerations.
Clinical Experience Narrative:
I remember when we first started using Provera extensively in our practice back in the late 90s - we were really enthusiastic about having this tool for managing heavy uterine bleeding without resorting to surgery. But it was Mrs. Henderson, 42-year-old teacher with menorrhagia that really taught me the nuances. She’d failed multiple other treatments and was facing hysterectomy when we started her on cyclic Provera. The first month was rough - breakthrough bleeding, mood swings that had her calling me twice weekly. My partner wanted to switch approaches but I argued we needed to give it 3 months. By month 3, her cycles regulated, hemoglobin normalized, and she avoided surgery. She’s been stable on maintenance dosing for 2 years now.
Then there was the learning curve with the depot formulation. We had a cluster of patients in 2008 who developed significant weight gain and mood changes - one young woman, Sarah Jenkins, actually discontinued despite perfect contraceptive efficacy because she said she “didn’t feel like herself.” That experience made me much more selective about which patients I recommend the injection for - now I reserve it mainly for women who have contraindications to estrogen-containing methods or need extended contraception.
The oncology applications have been particularly rewarding. Just last month I saw Maria Rodriguez, 35, with well-differentiated endometrial cancer who desperately wanted fertility preservation. We started high-dose Provera after thorough counseling about the experimental nature. Her 3-month follow-up biopsy showed complete resolution - the look on her face when I gave her the results was worth all the paperwork and prior authorization battles.
What’s surprised me most over the years is how individual the response can be. We’ve had patients on the same dosage with completely different experiences - some report improved energy and mood, others describe brain fog and fatigue. The metabolic effects vary tremendously too - some women show significant lipid changes, others have minimal laboratory alterations. This variability has made me much more humble about predicting outcomes.
The team disagreements have been interesting too - our endocrinologist remains skeptical about long-term use for anything beyond cancer treatment, while our GYN colleagues swear by it for perimenopausal management. The data doesn’t always give clear answers either - just last week we were debating whether to continue Provera in a 58-year-old with 10-year history of use for endometrial protection. The osteoporosis risk versus endometrial cancer protection calculus isn’t straightforward.
Long-term follow-up has revealed some patterns though - patients who do well initially generally maintain response, while those with side effects in the first month often struggle throughout therapy. The patients themselves have been my best teachers - one told me she times her doses around her work schedule to minimize cognitive side effects, another found that taking it with food reduced her nausea significantly. These practical insights never make it into the package insert but they’re crucial for successful management.
The most consistent feedback I get from long-term users? They appreciate having a treatment that doesn’t require daily administration (with the injection) or one that gives them predictable cycles. The women who’ve struggled with erratic bleeding for years particularly value the predictability Provera can provide when it works. It’s not perfect, but in the right patient, it remains a valuable tool in our therapeutic arsenal.